Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer.
Desai A, Smith CJ, Ashara Y, Orme JJ, Zanwar S, Potter A, Hocum C, Moffett JN, Schwecke AJ, Manochakian R, Lou Y, Zhao Y, Ernani V, Savvides P, Molina J, Dimou A, Mansfield AS, Parikh K, Leventakos K. Desai A, et al. Among authors: orme jj. Clin Lung Cancer. 2023 Dec;24(8):689-695.e1. doi: 10.1016/j.cllc.2023.09.001. Epub 2023 Sep 17. Clin Lung Cancer. 2023. PMID: 37880074 Free article.
ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance.
Orme JJ, Jazieh KA, Xie T, Harrington S, Liu X, Ball M, Madden B, Charlesworth MC, Azam TU, Lucien F, Wootla B, Li Y, Villasboas JC, Mansfield AS, Dronca RS, Dong H. Orme JJ, et al. Oncoimmunology. 2020 Apr 14;9(1):1744980. doi: 10.1080/2162402X.2020.1744980. eCollection 2020. Oncoimmunology. 2020. PMID: 32363112 Free PMC article.
Economic Cost and Sustainability of Oral Therapies in Precision Oncology.
Desai AP, Scheckel CJ, Soderberg LC, Jensen CJ, Orme JJ, Tella SH, Kommalapati A, Pritchett JC, Khera N, Mahipal A, Go RS; Mayo Clinic Hematology and ONcology Outcomes Research (HONOR) Group. Desai AP, et al. Among authors: orme jj. JCO Oncol Pract. 2022 Aug;18(8):e1247-e1254. doi: 10.1200/OP.21.00847. Epub 2022 May 26. JCO Oncol Pract. 2022. PMID: 35617640
Salvage therapy expands highly cytotoxic and metabolically fit resilient CD8+ T cells via ME1 up-regulation.
Gicobi JK, Mao Z, DeFranco G, Hirdler JB, Li Y, Vianzon VV, Dellacecca ER, Hsu MA, Barham W, Yan Y, Mansfield AS, Lin Y, Wu X, Hitosugi T, Owen D, Grams MP, Orme JJ, Lucien F, Zeng H, Park SS, Dong H. Gicobi JK, et al. Among authors: orme jj. Sci Adv. 2023 Nov 17;9(46):eadi2414. doi: 10.1126/sciadv.adi2414. Epub 2023 Nov 15. Sci Adv. 2023. PMID: 37967193 Free PMC article.
Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT-Identified Oligometastatic Castration-Resistant Prostate Cancer.
Zhang H, Orme JJ, Abraha F, Stish BJ, Lowe VJ, Lucien F, Tryggestad EJ, Bold MS, Pagliaro LC, Choo CR, Brinkmann DH, Iott MJ, Davis BJ, Quevedo JF, Harmsen WS, Costello BA, Johnson GB, Nathan MA, Olivier KR, Pisansky TM, Kwon ED, Dong H, Park SS. Zhang H, et al. Among authors: orme jj. Clin Cancer Res. 2021 Dec 1;27(23):6376-6383. doi: 10.1158/1078-0432.CCR-21-2510. Epub 2021 Sep 30. Clin Cancer Res. 2021. PMID: 34593526 Free PMC article. Clinical Trial.
A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and/or tumor mutation burden-high metastatic castration-resistant prostate cancer: outcome analysis.
Mosalem O, Tan W, Bryce AH, Dronca RS, Childs DS, Pagliaro LC, Orme JJ, Kase AM. Mosalem O, et al. Among authors: orme jj. Prostate Cancer Prostatic Dis. 2024 Feb 10. doi: 10.1038/s41391-024-00799-y. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 38341460
42 results